目的 探討穿龍骨刺膠囊聯(lián)合骨肽注射液治療骨質(zhì)增生的安全性和有效性。方法 選取信陽市第一人民醫(yī)院在2015年6月—2016年6月收治的骨質(zhì)增生患者177例，隨機分成對照組（88例）和治療組（89例）。對照組患者肌肉注射骨肽注射液，2 mL/次，1次/d；治療組患者在對照組的基礎(chǔ)上餐前口服穿龍骨刺膠囊，6粒/次，3次/d。所有患者均治療28 d。評價治療后兩組患者臨床療效，同時比較兩組患者治療前后兩組臨床癥狀積分、VAS評分和不良反應(yīng)發(fā)生情況。結(jié)果 治療后，對照組和治療組總有效率分別為79.55%、96.63%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，兩組患者麻木、疼痛、腫脹以及屈展困難等骨質(zhì)增生臨床癥狀積分均顯著降低（P< 0.05）；且治療組骨質(zhì)增生臨床癥狀積分均顯著低于對照組（P< 0.05）。治療后，兩組患者VAS評分與治療前相比顯著降低（P< 0.05）；且治療組VAS評分壓痛指數(shù)明顯低于對照組（P< 0.05）。治療期間，對照組患者不良反應(yīng)的發(fā)生率為15.91%，顯著高于治療組患者的5.62%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。結(jié)論 穿龍骨刺聯(lián)合骨肽注射液治療骨質(zhì)增生臨床療效好，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the safety and efficacy of Chuanlong Guci Capsules combined with Ossotide Injection in treatment of hyperostosis. Methods Patients (177 cases) with hyperostosis in the First People's Hospital of Xinyang City from June 2015 to June 2016 were randomly divided into control (88 cases) and treatment (89 cases) groups. Patients in the control group were im injected with Ossotide Injection on the basis of conventional treatment, 2 mL/time, once daily. Patients in the treatment group were po administered with Chuanlong Guci Capsules before meal on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 28 d. After treatment, clinical efficacy was evaluated, and clinical symptom score, VAS scores, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.55% and 96.63%, respectively, and there were differences between two groups (P < 0.05). After treatment, the clinical symptoms scores of numbness, pain, swelling, and difficulty in flexion and extension in two groups were significantly decreased (P < 0.05). And the clinical symptom scores of hyperostosis in treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the VAS scores in two groups were significantly decreased (P < 0.05). And the VAS scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the adverse reaction incidence in the control group was 15.91%, which was significantly higher than 5.62% in the treatment group, with significant difference between two groups (P < 0.05). Conclusion Chuanlong Guci Capsules combined with Ossotide Injection has good clinical efficacy in treatment of hyperostosis with high safety, which has a certain clinical application value.